270 related articles for article (PubMed ID: 32846644)
41. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms.
Raucci F; Mansour AA; Casillo GM; Saviano A; Caso F; Scarpa R; Mascolo N; Iqbal AJ; Maione F
Autoimmun Rev; 2020 Jul; 19(7):102572. PubMed ID: 32376393
[No Abstract] [Full Text] [Related]
42. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
43. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
[No Abstract] [Full Text] [Related]
45. Asthma and COVID-19: Is asthma a risk factor for severe outcomes?
Johnston SL
Allergy; 2020 Jul; 75(7):1543-1545. PubMed ID: 32358994
[No Abstract] [Full Text] [Related]
46. TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.
Mantovani S; Oliviero B; Varchetta S; Renieri A; Mondelli MU
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175768
[TBL] [Abstract][Full Text] [Related]
47. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
48. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
Mamber SW; Krakowka S; Osborn J; Saberski L; Rhodes RG; Dahlberg AE; Pond-Tor S; Fitzgerald K; Wright N; Beseme S; McMichael J
mSphere; 2020 May; 5(3):. PubMed ID: 32404512
[TBL] [Abstract][Full Text] [Related]
49. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need.
Zhang T; He Y; Xu W; Ma A; Yang Y; Xu KF
Sci China Life Sci; 2020 May; 63(5):774-776. PubMed ID: 32124179
[No Abstract] [Full Text] [Related]
50. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
Atal S; Fatima Z
Pharmaceut Med; 2020 Aug; 34(4):223-231. PubMed ID: 32535732
[TBL] [Abstract][Full Text] [Related]
51. Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.
Imami AS; O'Donovan SM; Creeden JF; Wu X; Eby H; McCullumsmith CB; Uvnäs-Moberg K; McCullumsmith RE; Andari E
Physiol Genomics; 2020 Sep; 52(9):401-407. PubMed ID: 32809918
[TBL] [Abstract][Full Text] [Related]
52. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
Chrousos GP; Meduri GU
Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
[No Abstract] [Full Text] [Related]
53. Oxytocin as a potential defence against Covid-19?
Soumier A; Sirigu A
Med Hypotheses; 2020 Jul; 140():109785. PubMed ID: 32344303
[No Abstract] [Full Text] [Related]
54. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.
McCarty MF; DiNicolantonio JJ
Prog Cardiovasc Dis; 2020; 63(3):383-385. PubMed ID: 32061635
[No Abstract] [Full Text] [Related]
55. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.
Guo H; Zheng J; Huang G; Xiang Y; Lang C; Li B; Huang D; Sun Q; Luo Y; Zhang Y; Huang L; Fang W; Zheng Y; Wan S
Ann Palliat Med; 2020 Sep; 9(5):3235-3248. PubMed ID: 32954754
[TBL] [Abstract][Full Text] [Related]
56. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
57. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19.
Berretta AA; Silveira MAD; Cóndor Capcha JM; De Jong D
Biomed Pharmacother; 2020 Nov; 131():110622. PubMed ID: 32890967
[TBL] [Abstract][Full Text] [Related]
58. Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.
Tiscornia JE; Poggio TV; Feinsilber DG; Coleman AE
Skinmed; 2020; 18(4):254-255. PubMed ID: 33050993
[No Abstract] [Full Text] [Related]
59. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
Conti P; Ronconi G; Caraffa A; Gallenga CE; Ross R; Frydas I; Kritas SK
J Biol Regul Homeost Agents; 2020 March-April,; 34(2):327-331. PubMed ID: 32171193
[TBL] [Abstract][Full Text] [Related]
60. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
